Centro de Investigacion Medico Asistencial S.A.S

Barranquilla 80020

5 studies enrolling now · 13 studies all time

What they study most

Cardiovascular Diseases, Chronic Cutaneous Lupus Erythematosus, Dermatomyositis, Diabetes Mellitus, Type 2, Dyslipidemia, Heart Failure, Hypertension, Lupus Erythematosus, Systemic, Primary Sjogrens Disease, Rheumatoid Arthritis, Subacute Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus

Studies at this site

• EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease — Recruiting now
• A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart — Recruiting now
• A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure — Recruiting now
• A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus — Enrolling by invitation
• An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus — Enrolling by invitation
• The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE) — Running, not enrolling
• A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis — Completed
• A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome — Running, not enrolling
• A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus — Running, not enrolling
• The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW) — Completed
• Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT) — Stopped early
• An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus — Stopped early
• A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350 — Completed